{"name": "Genzyme",
 "permalink": "genzyme",
 "crunchbase_url": "http://www.crunchbase.com/company/genzyme",
 "homepage_url": "http://www.genzyme.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "617-252-7500",
 "description": "",
 "created_at": "Wed Jan 26 05:38:26 UTC 2011",
 "updated_at": "Tue Oct 25 01:08:26 UTC 2011",
 "overview": "\u003Cp\u003EGenzyme Corporation (Genzyme) is a biotechnology company. The Company\u00e2\u20ac\u2122s product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune disease. Genzyme operates in four business segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery develops, manufactures and distributes biotherapeutics and biomaterial-based products. Hematologic Oncology develops, manufactures and distributes products for the treatment of cancer. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       50],
      "assets/images/resized/0011/9036/119036v1-max-150x150.png"],
     [[155,
       52],
      "assets/images/resized/0011/9036/119036v1-max-250x250.png"],
     [[155,
       52],
      "assets/images/resized/0011/9036/119036v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "David",
      "last_name": "Meeker",
      "permalink": "david-meeker",
      "image": null}},
   {"is_past": false,
    "title": "",
    "person":
     {"first_name": "Anthony",
      "last_name": "J. Sinskey",
      "permalink": "anthony-j-sinskey",
      "image":
       {"available_sizes":
         [[[140,
            140],
           "assets/images/resized/0027/5965/275965v1-max-150x150.png"],
          [[140,
            140],
           "assets/images/resized/0027/5965/275965v1-max-250x250.png"],
          [[140,
            140],
           "assets/images/resized/0027/5965/275965v1-max-450x450.png"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Chairman of the Board, President",
    "person":
     {"first_name": "Henri",
      "last_name": "A. Termeer",
      "permalink": "henri-a-termeer",
      "image": null}},
   {"is_past": true,
    "title": "Founder / Chairman / CEO",
    "person":
     {"first_name": "Sheridan",
      "last_name": "Snyder",
      "permalink": "sheridan-snyder",
      "image":
       {"available_sizes":
         [[[84,
            84],
           "assets/images/resized/0025/5157/255157v1-max-150x150.jpg"],
          [[84,
            84],
           "assets/images/resized/0025/5157/255157v1-max-250x250.jpg"],
          [[84,
            84],
           "assets/images/resized/0025/5157/255157v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "VP Global Marketing \u0026 Strategy",
    "person":
     {"first_name": "Hans",
      "last_name": "GCP Schikan",
      "permalink": "hans-gcp-schikan",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5868/275868v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5868/275868v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5868/275868v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Senior Vice President, Business Excellence",
    "person":
     {"first_name": "Anne",
      "last_name": "Merrifield",
      "permalink": "anne-merrifield",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0025/6811/256811v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0025/6811/256811v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0025/6811/256811v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Global Regulatory Systems and Program Management",
    "person":
     {"first_name": "Bryan",
      "last_name": "Ennis",
      "permalink": "bryan-ennis",
      "image": null}},
   {"is_past": true,
    "title": "Director Genzyme Netherlands",
    "person":
     {"first_name": "Hans",
      "last_name": "GCP Schikan",
      "permalink": "hans-gcp-schikan",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5868/275868v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5868/275868v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5868/275868v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Various Role",
    "person":
     {"first_name": "Roelck A",
      "last_name": "Cuperus",
      "permalink": "roelck-a-cuperus",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition":
  {"price_amount": 20000000000.0,
   "price_currency_code": "USD",
   "term_code": "cash",
   "source_url": "http://www.masshightech.com/stories/2011/02/14/daily28-Sanofi-paying-20B---and-then-some---for-Genzyme.html",
   "source_description": "Sanofi paying $20B - and then some - for Genzyme",
   "acquired_year": 2011,
   "acquired_month": 2,
   "acquired_day": 16,
   "acquiring_company":
    {"name": "Sanofi Aventis",
     "permalink": "sanofi-aventis-2",
     "image":
      {"available_sizes":
        [[[150,
           119],
          "assets/images/resized/0005/4534/54534v3-max-150x150.png"],
         [[150,
           119],
          "assets/images/resized/0005/4534/54534v3-max-250x250.png"],
         [[150,
           119],
          "assets/images/resized/0005/4534/54534v3-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "500 Kendall Street",
    "address2": "",
    "zip_code": " 02142",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Genzyme voluntarily repays $6M in MLSC incentives",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 25,
    "source_url": "http://www.masshightech.com/stories/2011/01/24/daily26-Genzyme-voluntarily-repays-6M-in-MLSC-incentives.html",
    "source_text": "",
    "source_description": "Genzyme voluntarily repays $6M in MLSC incentives",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genzyme",
      "permalink": "genzyme"}},
   {"description": "Genzyme closes $265M unit sale, plans another divestiture",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2011/01/31/daily17-Genzyme-closes-265M-unit-sale-plans-another-divestiture.html",
    "source_text": "",
    "source_description": "Genzyme closes $265M unit sale, plans another divestiture",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genzyme",
      "permalink": "genzyme"}},
   {"description": "officially announced the long-awaited approval of its sale to French pharmaceutical giant sanofi-aventis for approximately $20 billion in cash, well above sanofi\u00e2\u20ac\u2122s initial offer of approximately $18.5 billion",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 16,
    "source_url": "http://www.masshightech.com/stories/2011/02/14/daily28-Sanofi-paying-20B---and-then-some---for-Genzyme.html",
    "source_text": null,
    "source_description": "Sanofi paying $20B - and then some - for Genzyme",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genzyme",
      "permalink": "genzyme"}},
   {"description": "completed the divestiture of its pharmaceutical intermediates business to International Chemical Investors Group (ICIG)",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2011/02/28/daily29-Genzyme-completes-pharmaceutical-unit-sale.html",
    "source_text": null,
    "source_description": "Genzyme completes pharmaceutical unit sale",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genzyme",
      "permalink": "genzyme"}},
   {"description": "CEO Henri Termeer could get more than $200 million from the sale of his company to French drugmaker Sanofi-aventis SA",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 8,
    "source_url": "http://www.masshightech.com/stories/2011/03/07/daily18-Genzyme-CEO-Termeer-may-net-200M-payout.html",
    "source_text": null,
    "source_description": "Genzyme CEO Termeer may net $200M payout",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genzyme",
      "permalink": "genzyme"}},
   {"description": "Genzyme backs science fair with $50,000",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 14,
    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily10-Genzyme-backs-science-fair-with-50000.html",
    "source_text": "",
    "source_description": "Genzyme backs science fair with $50,000",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genzyme",
      "permalink": "genzyme"}},
   {"description": "made a $50,000 grant to support science fair programs in Massachusetts",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 14,
    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily10-Genzyme-backs-science-fair-with-50000.html",
    "source_text": null,
    "source_description": "Genzyme backs science fair with $50,000",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genzyme",
      "permalink": "genzyme"}},
   {"description": "Outgoing Genzyme Corp. chairman, CEO and president Henri A. Termeer has been appointed to the board of directors for Aveo Pharmaceuticals",
    "stoned_year": 2011,
    "stoned_month": 4,
    "stoned_day": 12,
    "source_url": "http://www.masshightech.com/stories/2011/04/11/daily21-Genzyme-CEO-Termeer-joins-Aveo-board.html",
    "source_text": null,
    "source_description": "Genzyme CEO Termeer joins Aveo board",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genzyme",
      "permalink": "genzyme"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:GENZ"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}